KDR and Telangiectasia: Some case reports already showed an improvement of epistaxis and telangiectasia in mostly HHT1 and two patients with different tyrosine kinase inhibitors (Robert et al., 2020; Snodgrass et al., 2021) targeting the VEGFR2 and the ANGPT2 receptor TIE2, which are overactivated in HHT.